Results 141 to 150 of about 2,887 (179)

Olmesartan-Associated Enteropathy With Severe Diarrhoea and Acute Kidney Injury. [PDF]

Cureus
Nikolaeva A, Della Vecchia A.
europepmc   +1 more source

Single-Pill Combination Olmesartan/Amlodipine/Hydrochlorothiazide Safety and Effectiveness in Older Patients with Hypertension: Pooled Analysis of Post-Approval Observational Studies. [PDF]

Adv Ther
Kim HJ, Kim HM, Kim DH.
europepmc   +1 more source

Drug-induced gastric motility disorders: A disproportionality analysis from the FAERS and CVARD databases. [PDF]

PLoS One
Qian Z, Jiang N.
europepmc   +1 more source

Protein Abundance of Hydrolytic Drug Metabolizing Enzymes in Different Tissues and across Species. [PDF]

J Med Chem
Subash S, Ahire D, Jones RS, Ma B, Tian Y, Wang T, Khojasteh SC, Murray BP, Stresser DM, Taub M, Prasad B.   +10 more
europepmc   +1 more source

Formulation and Evaluation of Olmesartan Medoxomil Tablets

Compounds, 2022
This work proposes a methodology for the design, development, and characterization of tablets prepared by the direct compression method of olmesartan medoxomil. The main objective was to ensure a high dissolution rate of the active ingredient. Therefore,
Mª Angeles Pena, Rocio Gonzalez Crespo
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Olmesartan Medoxomil

Drugs, 2002
Olmesartan medoxomil is a nonpeptide angiotensin II receptor antagonist which selectively and competitively inhibits the type 1 angiotensin II receptor without affecting other receptors regulating the cardiovascular system. In well designed randomised trials, olmesartan medoxomil was significantly more effective than placebo, and at dosages of 10 to 20
Gregory T, Warner, Blair, Jarvis
openaire   +2 more sources

Olmesartan Medoxomil/Amlodipine

Drugs, 2009
black triangle Olmesartan medoxomil/amlodipine is a fixed-dose combination of olmesartan medoxomil and amlodipine, both established antihypertensive agents. Dose titration with the individual constituent drugs is recommended before switching to the equivalent fixed-dose combination.
Mark, Sanford, Susan J, Keam
openaire   +2 more sources

Effects of the Angiotensin Receptor Blocker Azilsartan Medoxomil Versus Olmesartan and Valsartan on Ambulatory and Clinic Blood Pressure in Patients With Stages 1 and 2 Hypertension

Hypertension, 2011
Azilsartan medoxomil is an angiotensin receptor blocker (ARB) being developed for hypertension treatment. To compare this ARB with others in the class, we studied the effects of 2 doses of azilsartan medoxomil, with valsartan 320 mg and ...
William B White, Michael Weber, George Bakris   +2 more
exaly   +2 more sources

Olmesartan-medoxomil

Reactions Weekly, 2019
  +9 more sources